title: Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia.
abstract: Premature coronary heart disease (CHD) can result from high LDL cholesterol levels even in the absence of any other risk factors. A striking example is found in children who have the homozygous form of familial hypercholesterolemia (FH) with extremely high levels of LDL-cholesterol, and severe atherosclerosis and CHD often develop during the first decades of life. LDL-apheresis was developed for the treatment of severe type of FH patients who are resistant to lipid-lowering drug therapy. Clinical efficacy and safety of the therapeutic tool which directly removes LDL from circulation have already been established in the treatment for refractory hypercholesterolemia in FH patients. The most recently developed method enables lipoproteins to be adsorbed directly from whole blood, using polyacrylate column. In addition to benefits derived from the stabilization or regression of arterial lesions, we highlight other possible clinical applications of LDL-apheresis. However, most of these clinical benefits came from case reports or retrospective studies. Mechanisms related these clinical improvement remain unclear, and prospective randomized controlled trials should be performed for the new clinical indications of LDL-apheresis.
authors.affiliation: Department of Internal Medicine, Division of Cardiovascular Genetics, Graduate School of Medical Science, Kanazawa University, Takahara-machi 13-1, Kanazawa 920-8641, Japan. mabuchi@med.kanazawa-u.ac.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mabuchi
authors.forename: Toshinori
authors.initials: T
authors.lastname: Higashikata
authors.forename: Masa-Aki
authors.initials: MA
authors.lastname: Kawashiri
mesh_terms: D000924:Anticholesteremic Agents / Q000097:blood / Q000627:therapeutic use*; D001781:Blood Component Removal / Q000379:methods*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D002986:Clinical Trials as Topic; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000150:complications / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000097:blood*
chemical_list: D000924:Anticholesteremic Agents; D008077:Lipoproteins, LDL